Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (NAAT)™ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study

Substance use disorders (SUD) are inheritable and the culprit is hypodopaminergic function regulated by reward genes. We evaluated a natural dopaminergic agonist; KB220 intravenous (IV) and oral variants, to improve dopaminergic function in SUD. Our pilot experiment found a significant reduction of...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of psychoactive drugs Vol. 44; no. 5; pp. 398 - 409
Main Authors:	Miller, Merlene, Chen, Amanda LC, Stokes, Stan D., Silverman, Susan, Bowirrat, Abdalla, Manka, Matthew, Manka, Debra, Miller, David K., Perrine, Kenneth, Chen, Thomas JH, Bailey, John A., Downs, William, Waite, Roger L., Madigan, Margaret A., Braverman, Eric R., Damle, Uma, Kerner, Mallory, Giordano, John, Morse, Siobhan, Oscar-Berman, Marlene, Barh, Debmalya, Blum, Kenneth
Format:	Journal Article
Language:	English
Published:	United States Taylor & Francis Group 01-11-2012 Haight Ashbury Publications
Subjects:	Administration, Oral Adult Amino acids Amino Acids - administration & dosage Amino Acids - therapeutic use Behavior - drug effects Chronic Abstinence Symptom Severity (CASS) Scale Chronic Disease Cognition & reasoning Cognition - drug effects dopamine Dopamine Agonists - administration & dosage Dopamine Agonists - therapeutic use Drug use Emotions Emotions - drug effects Emotions - physiology Female Humans Injections, Intravenous KB220IV-neuroadaptagen amino-acid therapy (NAAT) Male Middle Aged Neuropsychological Tests Pilot Projects Recurrence Reward reward deficiency syndrome (RDS) Substance abuse treatment Substance Abuse Treatment Centers Substance Withdrawal Syndrome - psychology Substance-Related Disorders - rehabilitation
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Substance use disorders (SUD) are inheritable and the culprit is hypodopaminergic function regulated by reward genes. We evaluated a natural dopaminergic agonist; KB220 intravenous (IV) and oral variants, to improve dopaminergic function in SUD. Our pilot experiment found a significant reduction of chronic symptoms, measured by the Chronic Abstinence Symptom Severity (CASS) Scale. The combined group (IV and oral) did significantly better than the oral-only group over the first week and 30-day follow-up period. Next, the combination was given to129 subjects and three factors; Emotion, Somatic, and Impaired Cognition, with eigenvalues greater than one were extracted for baseline CASS-Revised (CASS-R) variables. Paired sample t-tests for pre and post-treatment scales showed significant declines (p = .00001) from pre- to post-treatment: t = 19.1 for Emotion, t = 16.1 for Somatic, and t = 14.9 for Impaired Cognition. In a two-year follow-up of 23 subjects who underwent KB220IV therapy (at least five IV treatments over seven days) plus orals for 30+ days: 21 (91%) were sober at six months, 19 (82%) having no relapse; 19 (82%) were sober at one year, 18 (78%) having no relapse; and 21 (91%) were sober two-years post-treatment, 16 (70%) having no relapse. We await additional research and advise caution in interpreting these encouraging results.
ISSN:	0279-1072 2159-9777
DOI:	10.1080/02791072.2012.737727